Trial Profile
A Post-shave Keloid Recurrence Study in Two Parts: A Biomarker Assessment Followed by a Randomized, Double-blind, Placebo Controlled Evaluation of Safety, Tolerability, and Efficacy of QAX576
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2020
Price :
$35
*
At a glance
- Drugs Dectrekumab (Primary)
- Indications Keloids
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 01 Jul 2014 New trial record